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Abstract
Background: Tuberculosis (TB) and human immunodeficiency virus (HIV) represent two of the greatest health threats in
African prisons. In 2010, collaboration between the Centre for Infectious Disease Research in Zambia, the Zambia Prisons
Service, and the National TB Program established a TB and HIV screening program in six Zambian prisons. We report data on
the prevalence of TB and HIV in one of the largest facilities: Lusaka Central Prison.
Methods: Between November 2010 and April 2011, we assessed the prevalence of TB and HIV amongst inmates entering,
residing, and exiting the prison, as well as in the surrounding community. The screening protocol included complete history
and physical exam, digital radiography, opt-out HIV counseling and testing, sputum smear and culture. A TB case was
defined as either bacteriologically confirmed or clinically diagnosed.
Results: A total of 2323 participants completed screening. A majority (88%) were male, median age 31 years and body mass
index 21.9. TB symptoms were found in 1430 (62%). TB was diagnosed in 176 (7.6%) individuals and 52 people were already
on TB treatment at time of screening. TB was bacteriologically confirmed in 88 cases (3.8%) and clinically diagnosed in 88
cases (3.8%). Confirmed TB at entry and exit interventions were 4.6% and 5.3% respectively. Smear was positive in only 25%
(n = 22) of bacteriologically confirmed cases. HIV prevalence among inmates currently residing in prison was 27.4%.
Conclusion: Ineffective TB and HIV screening programs deter successful disease control strategies in prison facilities and
their surrounding communities. We found rates of TB and HIV in Lusaka Central Prison that are substantially higher than the
Zambian average, with a trend towards concentration and potential transmission of both diseases within the facility and to
the general population. Investment in institutional and criminal justice reform as well as prison-specific health systems is
urgently required.
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Introduction
The Global Plan to Stop TB 2011–2015, launched in 2010 has
an overall aim to halve TB mortality and prevalence rates by 2015,
compared with a 1990 baseline. Specific objectives of this plan
include ensuring early diagnosis of all TB cases, including amongst
vulnerable populations such as prisoners [1].
The poor health and living conditions that facilitate transmis-
sion of tuberculosis and HIV in prisons are now widely
acknowledged to constitute a violation of human rights and a
public health threat [2]. Estimates of prison-related TB rates range
from 5 to 50 times higher than those in the general community in
both lower and middle income countries (LMIC) and industrial-
ized nations [3–7]. Despite the implications of such projections for
population health, there remain many gaps in our knowledge of
prison-related burden of disease. Due to the relatively few studies
conducted in this field, our understanding of TB and HIV rates in
prisons as compared to the wider community are often based on
estimates. In sub-Saharan Africa in particular, the true prevalence
of TB and HIV in prisons is often unknown, much less the
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proportion of disease acquired in prison. Meanwhile, the prison
conditions in many, if not most prisons in the region provide near-
perfect conditions for the spread of both HIV and TB [2].
In Zambia, despite progress in TB control and HIV treatment
in public sector health facilities, high rates of disease persist. TB
prevalence (all forms) in the general population is estimated at
352/100,000 [8]. However, a study in two communities of Lusaka
province found the prevalence of bacteriologically confirmed TB
to be much higher at 870/100,000 [9]. Nationwide HIV
prevalence is estimated to be 12.5% [10] while in Lusaka province
it is 21% [11]. Limited evidence exists for TB or HIV prevalence
in the country’s prisons with the most recent published studies
being conducted more than ten years ago; these reported an HIV
prevalence of 27% [12] and a conservative estimate for TB
prevalence of 4%, or 4000/100,000 [13]; both of these estimates
were substantially higher than national estimates at the time of the
studies.
A 2010 Human Rights Watch Report outlined conditions in
Zambian prisons including poor environmental, physical and
emotional circumstances in which inmates live and highlighting
the substantial risk these posed to inmate health [14]. That same
year, the Zambia Prisons Service (ZPS) and Zambian Ministry of
Health (MOH), in partnership with the Centre for Infectious
Disease Research in Zambia (CIDRZ) and the Zambia AIDS
Related TB Project (ZAMBART) obtained funds through the TB
REACH initiative of the Stop TB Partnership to establish a TB
and HIV screening program in six major prisons across three
provinces. An operations research component was included as part
of the program, to facilitate monitoring and evaluation and enable
the prevalence of TB and HIV in prisons to be reported to policy
makers and public health authorities. This paper reports data on
the prevalence of TB and HIV amongst inmates entering, residing
within and exiting the largest of those facilities – Lusaka Central
Prison.
Methods
Ethics Statement
The protocol was approved by the biomedical research ethics
committee of the University of Zambia (001-03-11), and the
institutional review board of the University of Alabama at
Birmingham (F101014011), United States of America. Both
institutions waived informed consent for participation in screening
activities since they were considered standard of care. Special
attention was paid to the vulnerable nature of this population in
the context of provider initiated HIV testing services. All HIV
counseling was conducted by experienced psycho-social counselors
in a private one-on-one setting. Inmates had the chance to opt-out
of HIV testing, or to choose not to receive the results if they did
test. No inmate was required to carry any form or indication of
results that may later identify him or her as HIV positive.
Setting
Lusaka Central Prison is a medium security facility, built in the
1923 by the British administration of then Northern Rhodesia.
Capacity of the facility was established at 200 inmates and its
location was on the outskirts of the recently established town of
Lusaka. By 2010, Lusaka Central Prison was housing between
1400 and 1500 inmates without any upgrade in infrastructure. In
modern-day Lusaka, the prison is located at the center of a densely
populated services area, which includes Zambia’s University
Teaching Hospital, and is adjacent to several low-income
residential areas or ‘compounds’. Inmates are a mixture of
convicted prisoners and remandees awaiting trial, with resultant
high turnover.
Intervention
Between November 2010 and April 2011 a TB and HIV
screening program was established in Lusaka Central prison. Prior
to the inception of the TB REACH program, a ZPS employed
clinical officer (CO) nominally provided a health review for
incoming inmates. However, human resource shortages meant
that reviews were cursory at best. The overall goal of the TB
REACH program was to develop systems and capacity to ensure
that TB and HIV screening were conducted for all inmates
coming into the facility, and that diagnosed cases received TB
and/or HIV treatment through established treatment programs
available within the prison or in neighboring clinics. The
intervention focused on building and/or upgrading infrastructure,
training staff to follow routine screening and diagnostic protocols
for TB and HIV, and training a cadre of inmate peer educators to
assist with information dissemination and case-finding.
The primary purpose of the screening program was to detect
and treat undiagnosed cases residing within the prison. Additional
objectives were to understand the prevalence of TB and HIV in
the facility and the surrounding prison camp community and
determine whether rates of disease were higher amongst exiting
inmates compared to entering inmates. We first screened a
consecutive sample of inmates exiting the prison (‘exit’ screening)
in order to capture the proportion with active TB released into the
community without the influence of the screening intervention.
We then conducted a comprehensive screening of all inmates
entering (‘entry’ screening) and residing within the prison (‘mass’
screening). Finally, we conducted a community screening for
prison staff and their families in the surrounding prison camp. All
individuals diagnosed with TB and/or HIV were referred to the
closest MOH health clinic for treatment. Table 1 lists the
screening activities in chronological order.
TB and HIV Screening Protocol
Entry and mass screening was an ongoing, two-day process.
Each day, prison management and inmate peer educators
produced lists of inmates to be screened and collected two spot
sputum samples from inmates irrespective of the presence of
symptoms. After providing sputum samples, inmates were referred
to a nurse or inmate peer educator for TB risk factor assessment
and symptom screening. Inmates were subsequently offered
provider initiated HIV testing and counseling (PITC) by a trained
lay counselor following WHO and Zambian national testing
guidelines. Testing was conducted using Determine HIV-1/2 test
(Abbott Laboratories, Abbott Park, USA) and confirmatory tests
using Uni-Gold HIV test (Trinity Biotech, Bray, Ireland). Inmates
who chose not to be tested for HIV continued with TB screening
procedures. Inmates were then referred to a mobile laboratory to
receive digital chest radiography (CXR). On Day 2, inmates were
reconvened for the CO to perform a physical examination, review
TB risk factors, symptoms, and smear results, interpret the CXR,
and make a determination on the diagnosis of TB.
Exit screening was conducted prior to other activities to evaluate
TB prevalence in inmates without the influence of the screening
intervention. The smaller sample size in this group enabled both
sputum specimens to cultured. However, because of the early
timing, the CXR unit was not yet available and inmates were not
evaluated for clinical TB. In addition, HIV test kits and counselors
were not yet available for the majority of inmates going through
exit screening and thus they were not offered PITC. All other
Tuberculosis and HIV in Zambian Prisons
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procedures were the same as in the mass and entry screening
protocol.
During community screening we used a door-to-door strategy to
cover the entire prison camp. While screening was available for all
individuals, budget constraints resulted in sputum samples being
collected only from individuals presenting with TB symptoms
and/or an abnormal CXR. As with the entry and mass screenings,
only one of the two sputum samples was sent for culturing. PITC
was offered as described in entry and mass screening.
Laboratory Procedures
Sputum smears were examined and digital CXRs (EasyDR,
Oldelft Benelux BV, NL) taken in an on-site semi-mobile 20-foot
container, custom fitted as a digital X-ray/smear microscopy unit.
All inmates had LED fluorescence microscopy (FM) (Primo Star
iLEDTMCarl Zeiss Microimaging, Oberkochen, Germany) per-
formed on two spot sputa. The highest quality specimen was then
transported the same day under controlled temperature conditions
to the TB department of the CIDRZ Central Laboratory, a BSL3
facility, for culturing. One sputum per inmate was cultured using
both liquid (BD BACTECTM MGITTM 960 Mycobacteria
Testing System) and solid (BD BBLTM Lowenstein-Jensen
Medium) culture. M. tuberculosis complex (MTBC) speciation and
drug susceptibility testing were done using line probe assay
(GenoType MDRTM, Hain Life Science GmbH, Germany).
Support was provided by the ZAMBART laboratory when extra
capacity was required.
TB Diagnosis
A TB case was defined as either bacteriologically confirmed or
clinically diagnosed. Bacteriologically confirmed cases were FM
smear and/or culture positive. Clinically diagnosed cases were FM
smear and culture negative, but had a CXR and/or signs and
symptoms that were considered clinically consistent with TB by a
trained CO. A patient was classified as ‘symptomatic’ if they had
any of cough, fever, night sweats or weight-loss. Extra-pulmonary
TB was diagnosed by a CO based on signs, symptoms and physical
exam findings.
Treatment of Diagnosed Cases
Patients diagnosed with TB were referred for initiation of anti-
tuberculosis therapy (ATT) at an MOH TB treatment center
adjacent to the prison facility. Patients not initially diagnosed with
TB, but later found culture positive for MTBC were referred for
ATT initiation upon receipt of culture results. Inmates who had
been discharged before culture results were received were traced
by community workers where possible.
Per national guidelines, patients found HIV-positive (regardless
of TB diagnosis) were referred for enrollment into HIV care and
treatment at the closest MOH HIV treatment center located two
kilometers from the prison facility.
Data Collection and Analysis
All data for this study were collected using standardized forms.
An onsite study coordinator provided the first level of quality
assurance by reviewing all files for completeness and plausible
responses and resolving apparent issues in real time. Following
screening, all forms were entered into a custom Microsoft Access
database by four data-entry clerks. FM smear results were
obtained daily from the microscopy laboratory register and culture
results were generated by the CIDRZ CLTB information system
in real-time as they became available. All data were exported into
SAS 9.2 (Cary, North Carolina, USA) for subsequent cleaning and
analysis. TB and HIV prevalence were calculated as proportions
and 95% confidence intervals. We used chi-squared tests to
compare (a) the prevalence of TB and HIV in different screening
groups and (b) history of prior incarceration among inmates with
and without TB and HIV. Requests for use of the raw data
supporting our results should be directed to the Zambian Ministry
of Home Affairs, Director of Prisons Health.
Results
Between November 2010 and April 2011, a total of 2,514
participants were screened at Lusaka Central Prison during entry,
mass, exit, and community screening. The average static inmate
population during that period was 1,300, however high inmate
turnover, particularly amongst remandees, contributed to our
screening almost double that number.
Of the 2,514 participants screened, 2,323 had complete
screening data and were included in the analysis. Screening
participants were 88% male, with a median age of 31 and median
body mass index (BMI) of 21.9. More than half (62%) of all those
screened had one or more of the WHO-recommended screening
symptoms of cough, fever, weight loss or night sweats, with the
most commonly recorded symptoms being cough (43%) and
weight loss (31%). Characteristics of screening participants are
outlined in Table 2.
Table 3 presents results across all TB screening interventions. A
total of 176 inmates (7.6%) were diagnosed with TB; 92%
(n= 162) of whom where male. This did not include 52 persons (49
male, 3 female) already diagnosed and receiving TB treatment at
the start of the program. The 176 cases consisted of 88
bacteriologically confirmed (3.8% of those screened) and 88
(3.8%) clinically diagnosed cases. Amongst the bacteriologically
confirmed cases, 33% (n= 29) were asymptomatic and FM smear
was positive in only 25% (n= 22). One of the culture confirmed
cases (1.1%) had multi-drug resistant TB (MDR-TB). A history of
incarceration was more common among inmates with bacterio-
Table 1. Schedule of Screening Activities.
Screening Phase Population Duration
Exit Screening All inmates prior to release from the prison to the
general community
November–February 2011
Mass Screening All inmates currently residing within the prison January–April 2011
Entry Screening All new inmates entering the prison February–April 2011
Community Screening Prison staff and their families living in the prison
camp community surrounding the prison
April 2011
doi:10.1371/journal.pone.0067338.t001
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logically confirmed TB (35.0%) than among inmates without TB
(24.8%; p= 0.04).
Entry screening captured 371 inmates, representing 100% of
inmates entering the facility during the intervention. Twenty-six
cases of active TB were diagnosed (7.0%), with 17 (4.6%)
bacteriologically confirmed and 9 (2.4%) clinically diagnosed.
During mass screening, a total of 1,362 inmates were evaluated. TB
was diagnosed in 119 (8.7%) inmates. Fifty-three (3.9%) were
bacteriologically confirmed and 66 (4.9%) were clinically diag-
nosed. At exit, a total of 188 inmates were screened and 101 (5.3%)
were diagnosed with TB; all of these cases were bacteriologically
confirmed. There was no statistically significant difference in the
prevalence of bacteriologically-confirmed TB between the entry,
mass, and exit screening groups (p = 0.79). During community
screening, 402 staff, family and community members were
screened and 21 (5.2%) cases of TB were diagnosed: eight
(2.0%) were bacteriologically confirmed, and 13 (3.2%) clinically
diagnosed.
HIV testing results and the prevalence of co-infection are shown
in Table 4. During entry screening 313 (84%) inmates had a known
prior status (positive at any time in the past or negative result in the
three months prior to screening) or accepted HIV testing, and
20.5% were HIV-positive. During mass screening, 1,247 (92%)
had a known prior status or accepted testing with 27.4% found
HIV-positive. The HIV prevalence during mass screening (27.4%)
was significantly higher than in inmates entering prison (20.5%,
p= 0.01). Due to limited staffing during the exit intervention,
PITC was offered to only 35/188 inmates screened at exit. Twelve
of these inmates (34.3%) were HIV positive. Because this is such a
small sample of our exiting inmates, we did not compare them
statistically to the other screening groups. A history of previous
incarceration was marginally more common amongst HIV-
positive inmates (27.3%) than amongst HIV-negative inmates
(22.7%; p= 0.06). Uptake of testing was also lower (58%) during
community screening, due to a higher refusal rate than in other
groups. Of those tested, 25% were HIV-positive.
Discussion
Our findings provide a critical first look at the joint burden of
TB and HIV disease in a large sub-Saharan African prison facility.
Although a number of prison studies have reported on either TB
[12,15–18] or HIV prevalence [13,19–22], to our knowledge, no
other study in sub-Saharan African prisons reports concurrently
on baseline prevalence for both diseases. In view of the well-
established biological and clinical linkages between TB and HIV,
the high baseline rates of infection in sub-Saharan Africa and the
acknowledged high-risk environment of prisons, these findings
thus constitute an important contribution to the evidence base.
Table 2. Population Characteristics.
Screening Intervention
Characteristic Entry (N=371) Mass (N=1362) Exit (N=188) Community (N=402) Total (N=2323)
Sex
Male, N (%) 368 (99.2%) 1293 (94.9%) 169 (89.9%) 205 (51.0%) 2035 (87.6%)
Female, N (%) 3 (0.8%) 69 (5.1%) 19 (10.1%) 197 (49.0%) 288 (12.4%)
Age, median (IQR) 28 (23–34) 32 (27–38) 32 (27–39) 25 (15–36) 31 (25–37)
History of TB
Past, N (%) 26 (7.0%) 111 (8.1%) 34 (18.1%) 22 (5.5%) 193 (8.3%)
Current, N (%) 1 (0.3%) 33 (3.4%) 2 (1.1%) 3 (0.8%) 39 (1.7%)
Prior history of incarceration, N (%) 88 (23.7%) 315 (23.1%) 82 (43.6%) 32 (8.0%) 517 (22.3%)
Presented with any cough, fever, night sweats or
weight loss
216 (58.2%) 825 (60.6%) 139 (73.9%) 250 (62.2%) 1430 (61.6%)
doi:10.1371/journal.pone.0067338.t002
Table 3. TB Prevalence.
Screening intervention Total Screened Already on ATT
Diagnosed at screening:
Bacteriological confirmed1
Diagnosed at screening:
Clinical diagnosis All forms TB
Entry 371 1 (0.3%) [0.0–1.5%] 17 (4.6%) [2.7–7.2%] 9 (2.4%) [1.1–4.6%] 27 (7.3%)
[4.9–10.4%]
Mass 1362 46 (3.4%) [2.5–4.5%] 53 (3.9%) [2.9–5.1%] 66 (4.9%) [3.8–6.1%] 165 (12.1%)
[10.4–14.0%]
Exit 188 2 (1.1%) [0.1–3.8%] 10 (5.3%) [2.6–9.6%] 0 (0%)2 [0–0.2%] 12 (6.4%)2
[3.3–10.9%]
Community 402 3 (0.7%) [0.2–2.2%] 8 (2.0%)3 [0.9–3.9%] 13 (3.2%) [1.7–5.5%] 24 (6.0%) [3.9–8.8%]
1Smear positive and/or culture positive for MTBC.
2Chest x-ray and clinical work-up were not performed for the majority of inmates screened in exit screening; thus there were no clinical diagnoses; as a result, all forms
TB was proportionally lower than in the other screening groups.
3During community screening, only symptomatic patients (N = 184) had sputum collected for smear and culture.
doi:10.1371/journal.pone.0067338.t003
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The prevalence of previously undiagnosed, bacteriologically
confirmed TB among inmates residing in Lusaka Central Prison
was 3900/100,000. This is 4.5 times the prevalence of bacterio-
logically confirmed TB found in the general population of Lusaka
Province [9]. HIV prevalence among inmates residing within
Lusaka Central Prison was found to be approximately twice that of
the national prevalence (27% vs 13.5%) [10] and 30% greater
than in Lusaka province (27% vs 21%) [11].
In Zambia, as elsewhere, individuals in poor health are likely to
be overrepresented amongst those who enter the criminal justice
system. This ‘concentration’ occurs in part because behavioral and
structural factors that contribute to poor health (e.g. unemploy-
ment, illicit drug use, poverty and alcoholism) also contribute to
the likelihood of incarceration. However, this concentration of
disease amongst inmates entering the system fails to account for
the increased prevalence of both TB and HIV disease seen
between the mass and exit screening protocols. Such an increase
suggests disease acquisition, not just concentration within the
facility.
HIV prevalence increased from entry (20%) to mass (27%)
screening, suggesting possible disease transmission within the
prison (Table 4). The prevalence at exit is even higher (34%), but
this figure should be interpreted with caution: it is based on a small
sample of exiting inmates and has a very large confidence interval
[19.1–52.2%]. Environmental conditions may promote HIV
transmission, with overcrowding contributing to normalization of
behaviors that facilitate disease-transmission such as violence and
unprotected sex. Similarly, adverse environmental conditions such
as poor nutrition, psychological stressors and limited access to
testing and treatment may contribute to disease progression, thus
increasing the risk of transmission when a person engages in risky
behaviors. Meanwhile, access to preventive interventions, psycho-
social and or other rehabilitative services remain currently weak or
non-existent [23–25].
While the overall TB prevalence was lower at exit screening
than at both entry and mass screening, this most likely reflects the
lack of CXR which prevented clinical diagnoses. A potential
explanation for the similar rates of TB at entry and mass
screenings is that most inmates entering the prison came from
police detention centers (jails) where they could have stayed
anywhere from a day to several months. The detention centers
have many environmental similarities to prisons and are probably
high-risk environments for TB transmission. Another potential
explanation is the ‘revolving door’ effect (Fig. 1). High rates of
active TB in the prison contribute to higher-than-normal rates of
latent TB infection (LTBI) among inmates. Continual inmate
turnover, and high rates of re-imprisonment (Table 2) make it
likely that re-offenders who were previously infected with LTBI,
develop active disease prior to their subsequent prison tour.
Conditions of extreme physical and emotional duress as well as
high rates of HIV infection likely also contribute to this trend. This
cycle of post-release morbidity, which in turn contributes to higher
rates of disease amongst re-offenders, is supported by our finding
of a significant association between prior imprisonment and
bacteriologically confirmed TB, and a trend towards an associa-
tion between prior imprisonment and HIV infection.
In addition to high rates of disease within the prison, the
prevalence of bacteriologically confirmed TB in the community
immediately surrounding the prison (2000/100,000) was more
than twice the prevalence found previously in Lusaka province [9].
While the study design here precludes causal inference, this finding
is suggestive of disease transmission between those working in the
prison and the general community (Fig. 1). In Lusaka Central
Prison, community contact occurred when inmates were released
from prison, when prison officers returned daily to their families
and friends outside the prison, and when inmates received visitors
from the outside community. This hypothesis is supported by
previous studies showing that the population attributable fraction
(PAF) of TB in the general community due to exposure in prisons
is substantial, with the median PAF among several studies in lower
to middle income countries being 6.3% (IQR:2.7–17.2%) [26].
The finding of low sensitivity of smear microscopy (25%) in this
study provides further evidence of the need for better and faster
tools to diagnose TB. Technologies such as the XpertHMTB/RIF
assay [27,28] are timely in this respect. Since 33% of the
bacteriologically confirmed TB cases identified in this study did
not report any of the typical screening symptoms of cough, fever,
weight loss or night sweats, our findings point to the need for an
algorithm based on different criteria to facilitate more aggressive
screening, diagnosis and treatment of prison-based cases.
Limitations
This study had several limitations. Due to operational
constraints, there was no CXR during the exit screening protocol;
this likely contributed to an underestimation of clinical disease in
this population. Conversely, the necessarily aggressive approach to
TB diagnosis in prison settings may have resulted in over-diagnosis
of clinical cases during the entry and mass screening interventions.
Table 4. HIV prevalence and TB/HIV co-infection.
Screening
Intervention
Total
Screened
Number with
known HIV
status1 HIV positive
Proportion of HIV+ persons
with bacteriologically-
confirmed TB
Proportion of HIV- persons
with bacteriologically-
confirmed TB
Proportion of
bacteriologically –
confirmed TB patients
that are HIV+
Entry 371 313 (84%)
[80–88%]
64 (20.5%)
[16.1–25.4%]
5/64 (7.8%) [2.6–17.3%] 9/249 (3.6%) [1.7–6.8%] 5/14 (35.7%) [12.8–64.9%]
Mass 1362 1247 (92%)
[90–93%]
342 (27.4%)
[25.0–30.0%]
22/342 (6.4%) [4.1–9.6%] 26/905 (2.9%) [1.9–4.2%] 22/48 (45.8%) [31.4–60.8%]
Exit 188 352 (19%)
[13–25%]
12 (34.3%)
[19.1–52.2%]
1/12 (8.3%) [0.2–38.5%] 1/23 (4.4%) [0.1–22.0%] 1/2 (50.0%) [1.3–98.7%]
Community 402 232 (58%)3
[53–63%]
57 (24.6%)
[19.2–30.6%]
7/57 (12.3%) [5.1–23.7%] 0/175 (0%) [0.0–2.1%] 7/7 (100%) [59.0–100%]
1Includes prior positives, persons who had tested negative within the 3 months prior to screening, and those who accepted PITC at screening.
2Due to staffing limitations and unavailability of test kits at screening start-up, the majority of inmates participating in exit screening were not offered PITC.
3The lower uptake of PITC in community screening is primarily due to persons declining HIV testing.
doi:10.1371/journal.pone.0067338.t004
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We sought to mitigate this by conducting training and refresher
courses in radiographic interpretation, standardizing report forms
and providing ongoing mentorship and quality control by a
trained infectious disease physician. The few persons tested for
HIV during exit screening reflected staff constraints and unavail-
ability of test kits; whereas community members were less likely to
accept HIV testing when offered. The lower acceptance of HIV
testing in community members is likely due to stigma; persons
were more accepting of TB screening because TB is less
stigmatized than HIV.
Rates of bacteriologically confirmed TB may have been
underestimated due to culturing only a single specimen per
inmate during entry, mass and community screening. Ideally we
would have cultured at least two specimens per inmate but this was
cost prohibitive. As the primary goal of the program was case
finding, we opted to screen a greater number of inmates with one
specimen rather than fewer inmates with two specimens. Each
specimen was cultured in solid and liquid media providing the
minimum reference standard and minimizing the difference in
yield between one and two specimens. In addition, time, space and
security constraints meant we relied on trained inmate peer
educators to assist in collection of sputum specimens during the
entry and mass screening interventions. This resulted in a lack of
consistency in specimen quality that may have affected TB yield,
as suggested by the high proportion of inmates who were culture
negative but with radiographic abnormalities consistent with TB.
Conclusion
In this paper, we describe extremely high rates of TB and HIV
in Lusaka Central Prison, and suggest mechanisms that may
contribute to disease concentration, and transmission. Although
confirming a widely held assumption, these findings constitute an
alert not only to the poor health of prison inmates, but to the way
poor prisoner health may threaten community disease control
efforts. To tackle this dual burden of disease, a coordinated
strategy among government institutions and stakeholders is
urgently needed to implement legislative and criminal justice
system reform, invest in institutional and health system upgrades
and enable preventive measures within the prison environment.
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